Treatment strategies for childhood stroke

Expert Opinion on Pharmacotherapy

Volumn 9, Issue 17, 2008, Pages 2955-2967

  Eleftheriou, Despina ^a   Ganesan, Vijeya ^b  

^a GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Anticoagulation therapy; Arterial ischaemic stroke; Aspirin; Children; Risk factors; Thrombolysis

Indexed keywords

ACETYLSALICYLIC ACID; ALTEPLASE; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; CYCLOPHOSPHAMIDE; DABIGATRAN ETEXILATE; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW MOLECULAR WEIGHT HEPARIN; STEROID; VASCULOTROPIN; WARFARIN;

ANTICOAGULATION; ARTERY DISSECTION; ARTERY SURGERY; BLEEDING; BRAIN HEMORRHAGE; BRAIN INJURY; BRAIN VASCULITIS; CEREBRAL REVASCULARIZATION; CEREBROVASCULAR ACCIDENT; CHILD; CHILD CARE; CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG DOSE REDUCTION; DRUG MECHANISM; DRUG MEGADOSE; ENDOVASCULAR SURGERY; EXCHANGE BLOOD TRANSFUSION; GASTRITIS; HEART DISEASE; HEART SURGERY; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; LOW DRUG DOSE; MOYAMOYA DISEASE; NEUROPROTECTION; NONHUMAN; OCCLUSIVE CEREBROVASCULAR DISEASE; ONSET AGE; OSTEOPOROSIS; RECOMMENDED DRUG DOSE; RECURRENT DISEASE; REVIEW; REYE SYNDROME; SICKLE CELL ANEMIA; THROMBOSIS PREVENTION; TRANSLUMINAL VALVULOPLASTY; VASCULAR DISEASE;

ANIMALS; ANTICOAGULANTS; BRAIN INJURIES; CHILD; HUMANS; MICROCIRCULATION; PLATELET AGGREGATION; STROKE; THROMBOLYTIC THERAPY;

EID: 57549088651     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656560802521650     Document Type: Review

References (88)

1. Ganesan V, Prengler M, Wade A, et al. Clinical and radiological recurrence after childhood arterial ischemic stroke. Circulation 2006;114:2170-7
2. Fullerton HJ, Wu YW, Sidney S, et al. Risk of recurrent childhood arterial ischemic stroke in a population-based cohort: the importance of cerebrovascular imaging. Pediatrics 2007;119:495-501
3. Kirton A, deVeber G. Therapeutic approaches and advances in pediatric stroke. NeuroRx 2006;3:133-42
4. Amlie-Lefond C, Sebire G, Fullerton HJ. Recent developments in childhood arterial ischaemic stroke. Lancet Neurol 2008;7:425-35
5. deVeber G. Stroke and the child's brain: an overview of epidemiology, syndromes and risk factors. Curr Opin Neurol 2002;15:133-8
6. Ganesan V, Prengler M, McShane MA, et al. Investigation of risk factors in children with arterial ischemic stroke. Ann Neurol 2003;53:167-73
7. deVeber G, Andrew M, Adams C, et al. Cerebral sinovenous thrombosis in children. N Engl J Med 2001;345:417-23
8. Delsing BJ, Catsman-Berrevoets CE, Appel IM. Early prognostic indicators of outcome in ischemic childhood stroke. Pediatr Neurol 2001;24:283-9
9. deVeber GA, MacGregor D, Curtis R, et al. Neurologic outcome in survivors of childhood arterial ischemic stroke and sinovenous thrombosis. J Child Neurol 2000;15:316-24
10. Ganesan V, Hogan A, Shack N, et al. Outcome after ischaemic stroke in childhood. Dev Med Child Neurol 2000;42:455-61
11. Lansing AE, Max JE, Delis DC, et al. Verbal learning and memory after childhood stroke. J Int Neuropsychol Soc 2004;10:742-52
12. Kwak CH, Jankovic J. Tourettism and dystonia after subcortical stroke. Mov Disord 2002;17:821-5
13. Friefeld S, Yeboah O, Jones JE, et al. Health-related quality of life and its relationship to neurological outcome in child survivors of stroke. CNS Spectr 2004;9:465-75
14. Gordon AL, Ganesan V, Towell A, et al. Functional outcome following stroke in children. J Child Neurol 2002;17:429-34
15. Monagle P, Chan A, Massicotte P, et al. Antithrombotic therapy in children: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest 2004;126:S645-87
16. Paediatric Stroke Working Group. Stroke in childhood: clinical guidelines for diagnosis, management and rehabilitation. Available from: http://www.rcplondon.ac.uk/pubs/books/childstroke/, accessed July 14 2008
17. Roach ES, Golomb MR, Adams R, et al. Management of stroke in infants and children: a scientific statement from a Special Writing Group of the American Heart Association Stroke Council and the Council on Cardiovascular Disease in the young. Stroke 2008;39:2644-91
18. British Committee on Standards in Haematology guideline on investigation and management of cerebral venous thrombosis in children. www.bcshguidelines.co.uk accessed July 14 2008
19. Hutchison JS, Ichord R, Guerguerian AM, et al. Cerebrovascular disorders. Semin Pediatr Neurol 2004;11:139-46
20. Baird TA, Parsons MW, Phanh T, et al. Persistent poststroke hyperglycemia is independently associated with infarct expansion and worse clinical outcome. Stroke 2003;34:2208-14
21. Gunn AJ, Wyatt JS, Whitelaw A, et al. Therapeutic hypothermia changes the prognostic value of clinical evaluation of neonatal encephalopathy. J Pediatr 2008;152:55-8
22. Correia M, Silva M, Veloso M. Cooling therapy for acute stroke. Cochrane Database Syst Rev 2000;CD001247
23. Haveman J, Sminia P, Wondergem J, et al. Effects of hyperthermia on the central nervous system: what was learnt from animal studies? Int J Hyperthermia 2005;21:473-87
24. Mcilvoy LH. The effect of hypothermia and hyperthermia on acute brain injury. AACN Clin Issues 2005;16:488-500
25. Wirrell EC, Armstrong EA, Osman LD, et al. Prolonged seizures exacerbate perinatal hypoxic-ischemic brain damage. Pediatr Res 2001;50:445-54
26. Castilo J, Leira R, Garcia MM, et al. Blood pressure decrease during the acute phase of ischemic stroke is associated with brain injury and poor stroke outcome. Stroke 2004;35:520-6
27. Cho DY, Chen TC, Lee HC. Ultra-early decompressive craniectomy for malignant middle cerebral artery infarction. Surg Neurol 2003;60:227-32
28. Clark WM, Wissman S, Albers GW, et al. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase thrombolysis for acute noninterventional therapy in ischemic stroke. JAMA 1999;282:2019-26
29. Hacke W, Kaste M, Fieschi C, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA 1995;274:1017-25
30. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995;333:1581-7
31. Amlie-Lefond C, Benedict SL, Benard T, et al. Thrombolysis in children with arterial ischemic stroke: initial results from the International Paediatric Stroke Study [abstract]. Stroke 2007;38:485
32. Benedict SL, Ni OK, Schloesser P, et al. Intra-arterial thrombolysis in a 2-year-old with cardioembolic stroke. J Child Neurol 2007;22:225-7
33. Belvis R. Thrombolysis for acute stroke in pediatrics. Stroke 2007;38:1722-3
34. Shuayto MI, Lopez JI, Greiner F. Administration of intravenous tissue plasminogen activator in a pediatric patient with acute ischemic stroke. J Child Neurol 2006;21:604-6
35. Bourekas EC, Slivka AP, Casavant MJ. Intra-arterial thrombolysis of a distal internal carotid artery occlusion in an adolescent. Neurocrit Care 2005;2:179-82
36. Janjua N, Nasar A, Lynch JK, et al. Thrombolysis for ischemic stroke in children: data from the nationwide inpatient sample. Stroke 2007;38:1850-4
37. Siegbahn A, Ruusuvaara L. Age dependence of blood fibrinolytic components and the effects of low-dose oral contraceptives on coagulation and fibrinolysis in teenagers. Thromb Haemost 1988;60:361-4
38. Gabis LV, Yangala R, Lenn NJ. Time lag to diagnosis of stroke in children. Pediatrics 2002;110:924-8
39. McGlennan C, Ganesan V. Delays in investigation and management of acute arterial ischaemic stroke in children. Dev Med Child Neurol 2008;50:537-40
40. Kirton A, Wong JH, Mah J, et al. Successful endovascular therapy for acute basilar thrombosis in an adolescent. Pediatrics 2003;112:e248-51
41. Cognard C, Weill A, Lindgren S, et al. Basilar artery occlusion in a child: 'clot angioplasty' followed by thrombolysis. Childs Nerv Syst 2000;16:496-500
42. International Paediatric Stroke Study Consortium recommendations on management of stroke. Available from: www.sickkids.on.ca/cstrokestudy accessed July 14 2008
43. Hirsh J, Warkentin TE, Shaughnessy SG, et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy and safety. Chest 2001;119:S64-94
44. Andrew M, Marzinotto V, Massicotte P, et al. Heparin therapy in pediatric patients: a prospective cohort study. Pediatr Res 1994;35:78-83
45. Strater R, Kurnik K, Heller C, et al. Aspirin versus low-dose low-molecular-weight heparin: antithrombotic therapy in pediatric ischemic stroke patients: a prospective follow-up study. Stroke 2001;32:2554-8
46. Massicotte P, Adams M, Marzinotto V, et al. Low-molecular-weight heparin in pediatric patients with thrombotic disease: a dose finding study. J Pediatr 1996;128:313-8
47. Newall F, Barnes C, Ignjatovic V, et al. Heparin-induced thrombocytopenia in children. J Paediatr Child Health 2003;39:289-92
48. Ansell J, Hirsh J, Poller L, et al. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126:S204-33
49. Eriksson BI, Smith H, Yasothan U, et al. Dabigatran etexilate. Nat Rev Drug Discov 2008;7:557-8
50. Eriksson BI, Dahl OE, Rosencher N, et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 2007;370:949-56
51. Eriksson BI, Dahl OE, Rosencher N, et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 2007;5:2178-85
52. DiChiara J, Bliden KP, Tantry US, et al. The effect of aspirin dosing on platelet function in diabetic and nondiabetic patients: an analysis from the aspirin-induced platelet effect (ASPECT) study. Diabetes 2007;56:3014-9.
53. Chen ZM, Sandercock P, Pan HC, et al. Indications for early aspirin use in acute ischemic stroke: a combined analysis of 40 000 randomized patients from the Chinese acute stroke trial and the international stroke trial. On behalf of the CAST and IST collaborative groups. Stroke 2000;31:1240-9
54. Zimmermann N, Weber AA, Hohlfeld T. Aspirin 'resistance. Herz 2008;33:270-8
55. Mohr JP, Thompson JL, Lazar RM, et al. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med 2001;345:1444-51
56. Schror K. Aspirin and Reye syndrome: a review of the evidence. Paediatr Drugs 2007;9:195-204
57. Mandava P, Thiagarajan P, Kent TA. Glycoprotein IIb/IIIa antagonists in acute ischaemic stroke: current status and future directions. Drugs 2008;68:1019-1028
58. Belvis R, Pagonabarraga J, Santamaria A, et al. Clopidogrel in secondary ischemic stroke prevention. Recent Patents Cardiovasc Drug Discov 2008;3:119-25
59. Soman T, Rafay MF, Hune S, et al. The risks and safety of clopidogrel in pediatric arterial ischemic stroke. Stroke 2006;37:1120-2
60. Park TS. Moyamoya disease in children. Neurosurg Focus 2008;24:E16a
61. Ozgur BM, Aryan HE, Levy ML. Indirect revascularisation for paediatric moyamoya disease: the EDAMS technique. J Clin Neurosci 2006;13:105-8
62. Khan N, Schuknecht B, Boltshauser E, et al. Moyamoya disease and Moyamoya syndrome: experience in Europe; choice of revascularisation procedures. Acta Neurochir (Wien) 2003;145:1061-71
63. Fung LW, Thompson D, Ganesan V. Revascularisation surgery for paediatric moyamoya: a review of the literature. Childs Nerv Syst 2005;21:358-64
64. Kirkham FJ. Therapy insight: stroke risk and its management in patients with sickle cell disease. Nat Clin Pract Neurol 2007;3:264-78
65. Adams RJ, McKie VC, Hsu L, et al. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. N Engl J Med 1998;339:5-11
66. Kirkham FJ, DeBaun MR. Stroke in children with sickle cell disease. Curr Treat Options Neurol 2004;6:357-75
67. Adams RJ, Brambilla D. Discontinuing prophylactic transfusions used to prevent stroke in sickle cell disease. N Engl J Med 2005;353:2769-78
68. Adams RJ. Lessons from the Stroke Prevention Trial in Sickle Cell Anemia (STOP) study. J Child Neurol 2000;15:344-9
69. DeBaun MR. Hydroxyurea as secondary prevention for stroke in children with sickle cell anemia J Pediatr 2005;147:560-1
70. Stroke With Transfusions Changing to Hydroxyurea (SWiTCH). Available from: http://www.clinicaltrials.gov/ct/show/NCT00122980?order_1 [Last accessed October 15 2008]
71. Elbers J, Benseler SM. Central nervous system vasculitis in children. Curr Opin Rheumatol 2008;20:47-54
72. Miravet E, Danchaivijitr N, Basu H, et al. Clinical and radiological features of childhood cerebral infarction following varicella zoster virus infection. Dev Med Child Neurol 2007;49:417-22
73. Lanthier S, Armstrong D, Domi T, et al. Post-varicella arteriopathy of childhood: natural history of vascular stenosis. Neurology 2005;64:660-3
74. Rafay MF, Armstrong D, Deveber G, et al. Craniocervical arterial dissection in children: clinical and radiographic presentation and outcome. J Child Neurol 2006;21:8-16
75. Kumar K. Neurological complications of congenital heart disease. Indian J Pediatr 2000;67:S15-9
76. Crowley RW, Medel R, Dumont AS. Evolution of cerebral revascularization techniques. Neurosurg Focus 2008;24:E3
77. Ciccone A, Canhao P, Falcao F, et al. Thrombolysis for cerebral vein and dural sinus thrombosis. Cochrane Database Syst Rev 2004;CD003693
78. Griesemer DA, Theodorou AA, Berg RA, et al. Local fibrinolysis in cerebral venous thrombosis. Pediatr Neurol 1994;10:78-80
79. Zheng Z, Chen B. Effects of pravastatin on neuroprotection and neurogenesis after cerebral ischemia in rats. Neurosci Bull 2007;23:189-97
80. Nassief A, Marsh JD. Statin therapy for stroke prevention. Stroke 2008;39:1042-8
81. Amarenco P, Goldstein LB, Szarek M, et al. Effects of intense low-density lipoprotein cholesterol reduction in patients with stroke or transient ischemic attack: the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Stroke 2007;38:3198-204
82. Lindvall O, Bjorklund A. Cell replacement therapy: helping the brain to repair itself. NeuroRx 2004;1:379-81
83. Lindvall O, Kokaia Z. Stem cells for the treatment of neurological disorders. Nature 2006;441:1094-6
84. Greenberg DA, Jin K. From angiogenesis to neuropathology. Nature 2005;438:954-9
85. Kaya D, Gursoy-Ozdemir Y, Yemisci M, et al. VEGF protects brain against focal ischemia without increasing blood - brain permeability when administered intracerebroventricularly. J Cereb Blood Flow Metab 2005;25:1111-8
86. Jin KL, Mao XO, Greenberg DA. Vascular endothelial growth factor: direct neuroprotective effect in in vitro ischemia. Proc Natl Acad Sci USA 2000;97:10242-47
87. Zhang ZG, Zhang L, Jiang Q, et al. VEGF enhances angiogenesis and promotes blood - brain barrier leakage in the ischemic brain. J Clin Invest 2000;106:829-38
88. Available from: https://app3.ccb.sickkids.ca/cstrokestudy/